Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We have strong track record of international clearances, including CE and UKCA approval of our latest AI power software |
| We are excited about the catalyst for our business in 2024 and we are pleased to have the cash and flexibility and to invest in the right areas for continued Swoop System adoption |
| Together, these advancements to address Alzheimer's disease offer an enormous incremental opportunity for brain imaging |
| I am pleased with the growth we delivered as we continue to lead the development of this new category of ultra-low field grade MRI with our unique portable Swoop system |
| We are very fortunate that we have been in the background working to give ourselves the international optionality as we have made a lot of progress on regulatory clearances with the CE mark under NDR, not the old NDD, and the UKCA certification, which is now of course, required after Brexit |
| I'm also incredibly enthusiastic by this international expansion that we have mentioned, which is not a peanut butter approach |
| I feel very confident in the way our customer success team is implementing programs |
| We're very pleased that we are continuing to build traction with new U.S |
| In 2024, we have a strong cadence of technology iterations across hardware and AI-powered software planned to further advance the image quality, the speed of image acquisition, clinical utility, ease of use, and clinical applications of ultra-low-field MRI |
| Before I turn the line over to Brett, I would like to reflect on the strong progress we have made over the past year, and the fact that we have demonstrated our ability to drive meaningful progress on our three strategic pillars while significantly reducing spending |
| However, as we go forward, we've been very proud of sort of record ASPs |
| I've remained incredibly optimistic about what we're building and the future of our business |
| Further, our Swoop implementation programs run by our clinical support team are yielding strong user advocates and champions across different departments inside the hospital setting |
| I'm proud of the execution of the team, the transformation of our financial profile, and the strong foundation we have established for the future of our business |
| And as I highlighted in the previous question, we're improving margin from we posted 43% gross margin in 2023 and our guidance is 45% to 50% for 2024 |
| In terms of the mechanics of getting to that number, as I highlighted, we have a margin guidance of 45 to 50, so an improvement from where we have been in 2023 and we'll be continued to be very laser disciplined in our spending, but continue to fund the innovation and growth opportunities that we see going forward |
| So, when I think about our priorities, there is a steady progress on adoption and commercialization, which continues to drive very healthy growth, but that's not the only thing on our board to do |
| There is a strong potential fit for Swoop to assist in reducing barriers to accessible and equitable Alzheimer's care |
| These have translated into strong growth, gross margin improvement, and cash flow reduction |
| We are very pleased to be driving healthy gross margins in our business, even at small scale |
| So, I'm very confident in telling you that we do not lose deals, that we end up with a very strong and predictable process to what we call the clinical yes from the initial pitch, but we do go into a relatively variable phase still in the administrative section of deals all the way to closing, which sometimes goes into quiet mode for a bit and coming back up |
| I'm proud of the progress the Hyperfine team made in 2023 and I remain very optimistic as to what we see can deliver |
| I am very encouraged by the level of interest and activity we're seeing for the Swoop System internationally, and I remain excited about global expansion as a growth opportunity this year and beyond |
| They are our ability to really land deals in flagship institutions and then translate those into very powerful initial successes with their use of our device in patients that otherwise would have had a very different prognosis or outcome or time frame |
| Our portable Swoop system is highly differentiated for this use case and the ideal technology for patients taking APP, providing a versatile, convenient and streamlined alternative to conventional MRI |
| With the FDA approval and CMS reimbursement of Biogen Eisai LEQEMBI and Amyloid Targeting Therapy, or ATT, as well as advancements in blood testing for the diagnosis of Alzheimer's and separately milestones related to additional coverage of PET scans to enable Alzheimer's diagnosis |
| Looking at growth margins, we are initiating a range of 45% to 50% for the year as we grow, continue our commercial sales traction, and realize strong, smooth system pricing |
| We have exercised strong spending discipline, and we are doing more with less across our operating [key] (ph) expense lines without compromising investment in our three strategic pillars: innovation, clinical evidence, and commercialization, with the outmost focus on execution and operating team |
| We entered 2024 with a stable of reference sites and a deeper understanding of how to target and build strong Swoop programs which positions us well for further expansion |
| I am pleased with the deal traction we have seen so far in 2024, many of [which] (ph) started and were cultivated in 2023 |
| Statement |
|---|
| Our full-year cash burn of $42 million is down 40% from $71 million in 2022 |
| For the full-year net loss of $44.3 million is down 39.5% from $73.2 million in the prior year |
| This scanning requirement also creates significant care navigation challenges for patients on these drugs who must add imaging to their already complex monitoring and infusion schedule |
| Maybe just starting off with Q4, it's usually the strongest quarter for capital businesses, but you did come in a little bit below at least on the revenue side, the low-end of your guidance range |
| Net loss for the fourth quarter was $10.7 million, equating to a net loss of $0.15 per share as compared to a net loss of $13.1 million or a net loss of $0.19 per share for the same period of the prior year |
| So, the cash flow from operation was negative $42 million in 2023 and then the current 2024 guidance of cash burn is about $40 million while we have increased revenue and potentially lower cost |
| The developments have also brought two issues to the forefront |
| As many of you know, there are currently over 50 million people suffering from Alzheimer's disease globally, and the cost and burden to patients and healthcare systems is enormous |
| Brett Hale Yes, I would add to the other point is that going back to the, I guess, confidence in the guidance |
| For the full-year, R&D expenses were $22.5 million, down from $28.2 million in the prior year, representing a 20% reduction |
Please consider a small donation if you think this website provides you with relevant information